Can liver damage predict how drugs behave?
NCT ID NCT07750587
First seen Aug 06, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This trial investigates how the severity of liver cirrhosis changes the way the body processes certain drugs. Adults with mild, moderate, or severe cirrhosis will receive a single low dose of five common drugs—caffeine, warfarin, esomeprazole, metoprolol, and midazolam—each used to measure the activity of a different liver enzyme. Blood samples taken over 72 hours will show how quickly the drugs are cleared from the body. The goal is to improve future drug dosing for people with liver cirrhosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A single low dose of five drugs: caffeine, warfarin, esomeprazole, metoprolol, and midazolam
- What this could lead to
- If successful, this could lead to better drug dosing guidelines for people with liver cirrhosis, reducing risks of ineffective treatment or side effects.
- What could go wrong
- This is a small, early-stage study focused on understanding drug processing, not on treating cirrhosis. Results may not apply to all patients or lead directly to new dosing recommendations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Better crystal ball for liver crisis: new scores put to the test
- Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test
- Stick-On ultrasound patch could spot liver damage without a specialist
- Blood test and AI could spot liver cancer early, saving lives